Advertisement

HindustanTimes Wed,16 Apr 2014

Cipla gets R73 cr NPPA notices for overpricing

PTI  new delhi, December 28, 2010
First Published: 21:58 IST(28/12/2010) | Last Updated: 22:00 IST(28/12/2010)

Drug firm Cipla said on Tuesday that it has received fresh notices from National Pharmaceutical Pricing Authority (NPPA) for R73.16 crore for overpricing of two drugs.

Advertisement

The company has received further demand notices from the Government demanding an amount of R47.7 crore in respect of the drug salbutamol and an amount of R25.5 crore in respect of the drug ciprofloxacin, Cipla said in a filing to the Bombay Stock Exchange (BSE).

“These demands are contrary to the orders of the Supreme Court of India and the company has received legal advice that entire amount demanded by the Government is not tenable and sustainable,” the company said.

Leading pharmaceutical firms Cipla and Ranbaxy are among those which have been pulled up by the NPPA for overcharging. According to the NPPA website, as on October 31, 2010, the total estimated overcharged amount, including interest, by various pharma companies since the inception of the NPPA in 1997 was R2,208.4 crore.

So far, the authority has recovered only R202.2 crore, and is locked in litigations in several courts to recover the rest. The NPPA was established on August 29, 1997 as an independent body of experts with the task of fixing and revising drug prices, both bulk drugs and formulations, to ensure their availability.

Advertisement
more from Business

Ranbaxy: From industry poster boy to problem child

For Ranbaxy Laboratories, which is nursing a welter of festering wounds from run-ins with regulators to employee exits and penalties for felonies, a change in ownership marks yet another milestone in its nearly five-decade old history.
markets
Advertisement
Most Popular
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved